Short Post-surgical Antibiotic Therapy in Spine Infections - a Prospective, Randomized, Unblinded, Non-inferiority Trial
Launched by BALGRIST UNIVERSITY HOSPITAL · Aug 5, 2019
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the length of antibiotic treatment needed after surgery for spine infections. Researchers want to find out if shorter courses of antibiotics (three to six weeks) are just as effective as longer ones (six to twelve weeks) for patients who have had surgery to clean out the infection. The study will involve two groups: one group will receive the longer antibiotic treatment if they have an implant in place, while the other group will receive shorter treatment if they do not have an implant.
To participate in this trial, you should have had spine surgery to treat a bacterial infection and be scheduled for follow-up for at least a year. Some individuals, such as those with certain types of infections or recent organ transplants, won’t be eligible. If you join the trial, you will be randomly assigned to one of the two treatment groups, and the study will monitor your recovery over time. This research is important because it could help determine the best length of antibiotic treatment after surgery, potentially leading to better care for patients with spine infections.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Spine surgery and intraoperative debridement with any technique
- • At least 12 months of scheduled follow-up from hospitalization
- • Bacterial spine infection of any nature, independently of implants or co-morbidities
- Exclusion Criteria:
- • Mycobacterial, fungal, nocardial, and Actinomyces infections in the spine
- • Non-resected cancer in the infection site
- • Bone marrow or recent solid organ transplant patient (Recent: \<5 years)
- • Any other infection in the patient requiring more than 6 weeks of antibiotic therapy
- • More than three intraoperative debridements performed for spine infection
- • Absence of at least one surgical intraoperative debridement of infection
About Balgrist University Hospital
Balgrist University Hospital is a leading academic medical center based in Zurich, Switzerland, renowned for its expertise in musculoskeletal health and rehabilitation. As a prominent sponsor of clinical trials, the hospital is dedicated to advancing medical research and improving patient outcomes through innovative studies in orthopedics, neurology, and rehabilitation sciences. With a strong commitment to interdisciplinary collaboration and patient-centered care, Balgrist University Hospital leverages its state-of-the-art facilities and a team of experienced researchers to drive clinical advancements and foster the translation of scientific discoveries into practical therapies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Zürich, Zurich, Switzerland
Patients applied
Trial Officials
Ilker Uckay, PD Dr med
Study Director
Balgrist University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials